Disease · MONDO_0006474

transitional cell carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. transitional cell carcinoma. Diseases, record MONDO_0006474. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006474

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: transitional cell carcinoma; Open Targets
Open Targets ID: MONDO_0006474; Open Targets
Other names: carcinoma of transitional epithelial cell, carcinoma of urothelial cell, carcinoma, urothelial, malignant, transitional carcinoma, transitional cell tumor, transitional epithelial cell carcinoma, urothelial cell carcinoma; Open Targets
Disease Ontology: DOID:2671; Disease Ontology
MeSH: D002295; MeSH
NCI Thesaurus: C2930; NCI Thesaurus
Highest stage of its drugs: Approval, for 5 of its 45 drugs, from EMA Human Drugs; Open Targets

Drugs45

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
PEMBROLIZUMAB	CHEMBL3137343	Antibody	Approval	EMA Human Drugs	4	3	3	Drugs and targets
NIVOLUMAB	CHEMBL2108738	Antibody	Approval	EMA Human Drugs	3	2	2	Drugs and targets
ATEZOLIZUMAB	CHEMBL3707227	Antibody	Approval	EMA Human Drugs	2	1	1	Drugs and targets
VINFLUNINE	CHEMBL2110725	Small molecule	Approval	EMA Human Drugs	2	1	1	Drugs and targets
ENFORTUMAB VEDOTIN	CHEMBL3301589	Antibody drug conjugate	Approval	EMA Human Drugs	1	0	0	Drugs and targets
CISPLATIN	CHEMBL11359	Small molecule	Phase 3	ClinicalTrials.gov	6	6	6	Drugs and targets
MITOMYCIN	CHEMBL105	Small molecule	Phase 3	ClinicalTrials.gov	3	3	3	Drugs and targets
BEVACIZUMAB	CHEMBL1201583	Antibody	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
GEMCITABINE HYDROCHLORIDE	CHEMBL1637	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
DURVALUMAB	CHEMBL3301587	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

1 to 10 of 45

See all 45 drugs

Targets90

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
KDR	Vascular endothelial growth factor receptor	5	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
TUBA1A	Tubulin	5	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	5	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	5	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	5	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	5	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	5	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	5	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	5	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/81027	Drugs and targets
TUBB2A	Tubulin	5	Tubulin inhibitor	Approval	https://conductscience.org/library/genes/7280	Drugs and targets

1 to 10 of 90

See all 90 targets

Trials40

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02516241	Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer	Phase 3	1,126	2021-05-13	Urothelial Cancer	DURVALUMAB, TREMELIMUMAB	Its record names the disease	ClinicalTrials.gov
NCT00942331	Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer	Phase 3	506	2020-02-17	Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Prostate Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Stage IV Bladder Urothelial Carcinoma AJCC v7, Stage IV Prostate Cancer AJCC v7, Stage IV Renal Pelvis Cancer AJCC v7, Stage IV Ureter Cancer AJCC v7, Stage IV Urethral Cancer AJCC v7, Unresectable Urothelial Carcinoma	BEVACIZUMAB, CISPLATIN, GEMCITABINE HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00880334	Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC	Phase 2	149	2014-06-04	Transitional Cell Carcinoma, Bladder Cancer	DOCETAXEL, VANDETANIB	Its record names the disease	ClinicalTrials.gov
NCT02401542	Dose Escalation, Expansion Study of Vofatamab (B-701) in Treatment of Locally Advanced or Metastatic Urothelial Cell Carcinoma	Phase 1/2	71	2020-02-17	Locally Advanced or Metastatic Urothelial Cell Carcinoma, Urinary Bladder Disease, Urological Diseases	DOCETAXEL, VOFATAMAB	Its record names the disease	ClinicalTrials.gov
NCT02619253	Phase I/Ib Study of Pembrolizumab With Vorinostat for Patients With Advanced Renal or Urothelial Cell Carcinoma	Phase 1	52	2024-11-18	Renal Cell Carcinoma, Urinary Bladder Neoplasms	PEMBROLIZUMAB, VORINOSTAT	Its record names the disease	ClinicalTrials.gov
NCT00588666	Phase II Trial of Gemcitabine, Carboplatin, and Bevacizumab in Chemotherapy Naive Patients With Advanced/Metastatic Urothelial Carcinoma	Phase 2	51	2016-01-22	Myeloproliferative Disorder, Urothelial Carcinoma, Cancer	BEVACIZUMAB, CARBOPLATIN, GEMCITABINE	Its record names the disease	ClinicalTrials.gov
NCT00583349	Intravesicular Abraxane for Treatment-Refractory Bladder Cancer	Phase 1/2	46	2025-02-17	Bladder Cancer	PACLITAXEL	Its record names the disease	ClinicalTrials.gov
NCT00478361	Gemcitabine, Paclitaxel, Doxorubicin in Metastatic or Unresectable Bladder Cancer With Decreased Kidney Function	Phase 2	40	2020-10-09	Distal Urethral Cancer, Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Proximal Urethral Cancer, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Regional Transitional Cell Cancer of the Renal Pelvis and Ureter, Stage III Bladder Cancer, Stage IV Bladder Cancer, Transitional Cell Carcinoma of the Bladder, Urethral Cancer Associated With Invasive Bladder Cancer	DOXORUBICIN, GEMCITABINE, PACLITAXEL, PEGFILGRASTIM	Its record names the disease	ClinicalTrials.gov
NCT00749892	Erlotinib Hydrochloride in Treating Participants With Muscle Invasive or Recurrent Urothelial Cancer	Phase 2	34	2020-09-10	Recurrent Bladder Urothelial Carcinoma, Recurrent Renal Pelvis Urothelial Carcinoma, Recurrent Ureter Urothelial Carcinoma, Recurrent Urethral Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0a Renal Pelvis Cancer AJCC v8, Stage 0a Ureter Cancer AJCC v8, Stage 0a Urethral Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage 0is Renal Pelvis Cancer AJCC v8, Stage 0is Ureter Cancer AJCC v8, Stage 0is Urethral Cancer AJCC v8, Stage II Bladder Cancer AJCC v8, Stage II Renal Pelvis Cancer AJCC v8, Stage II Ureter Cancer AJCC v8, Stage II Urethral Cancer AJCC v8, Stage III Renal Pelvis Cancer AJCC v8, Stage III Ureter Cancer AJCC v8, Stage III Urethral Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8	ERLOTINIB HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00710970	Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment	Phase 2	28	2013-08-22	Urinary Bladder Neoplasms	TAMOXIFEN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 40

See all 40 trials

Comparisons in its trials6

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Arm II (GCB) vs Arm I (GCP): deaths from any cause	207 of 252	216 of 254	506	NCT00942331	Trial comparisons
Arm II (GCB) vs Arm I (GCP): Number of Patients Experiencing Grade 3+ Toxicity	183 of 237	163 of 232	469	NCT00942331	Trial comparisons
Arm II (GCB) vs Arm I (GCP): serious adverse events	95 of 237	87 of 232	469	NCT00942331	Trial comparisons
Treatment (Sapanisertib): TSC Mutation 1 vs TSC Mutation 2: deaths from any cause	10 of 12	3 of 3	15	NCT03047213	Trial comparisons
Treatment (Sapanisertib): TSC Mutation 1 vs TSC Mutation 2: serious adverse events	6 of 12	2 of 3	15	NCT03047213	Trial comparisons
Dose Finding Cohort Dose Level 1 vs Dose Finding Cohort Dose Level 2: Number of Patients Experiencing a Dose Limiting Toxicity	0 of 3	0 of 3	6	NCT02619253	Trial comparisons

Papers from its trials32

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
24490762	RESULT	1	PubMed
18833002	RESULT	1	PubMed
15911238	RESULT	1	PubMed
15812833	RESULT	1	PubMed
42499790	DERIVED	1	PubMed
41995270	DERIVED	1	PubMed
41892875	DERIVED	1	PubMed
41672597	DERIVED	1	PubMed
40591902	DERIVED	1	PubMed
40588371	DERIVED	1	PubMed

1 to 10 of 32

See all 32 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006474

GET https://conductscience.org/api/diseases/v1/MONDO_0006474/drugs?page=2

API reference For AI assistants